Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxford BioMedica has entered into a research and development collaboration with the US-based Mayo Clinic for the development of novel gene therapy to treat chronic glaucoma.
Subscribe to our email newsletter
As per the agreement, Mayo Clinic and Oxford BioMedica will take up clinical studies on glaucoma treatment using Oxford BioMedica’s LentiVector gene delivery technology.
The technology expresses a COX-2 gene and a PGF-2a receptor gene in order to reduce intraocular pressure.
Under the terms of the collaboration, Oxford BioMedica can exercise the exclusive US rights to license Mayo Clinic’s glaucoma technology, following the completion of pre-clinical studies.